C4 Therapeutics, Inc. CCCC
As ofNov 20, 2026, 3:58 PM EST
- YTD
- +30.89%
- 1 year
- +5.04%
5D -0.28 (-10.29%)
- Market cap
- 328.29M
- Revenue (ttm)
- 33.67M
- EPS (ttm)
- -0.63
- Shares out
- 70.59M
- Forward P/E
- -2.37
- YTD return
- +30.89%
- 1-year return
- +5.04%
- 50-day average
- 5.06
- 200-day average
- 5.96
- Volume
- 3.31M
- Avg volume
- 2.54M
- Open
- 2.39
- Previous close
- 2.44
- Day's range
- 2.32 – 2.55
- 52-week range
- 1.71 – 4.67
- Beta
- 3.06
- Analysts
- Buy
- Price target
- 15.00 (+500.0%)
Key statistics
- Enterprise value
- 90.28M
- Price / sales
- 8.51
- Price / book
- 1.18
- Revenue growth
- 38.70%
- Free cash flow
- -41.84M
- Total cash
- 255.64M
- Total debt
- 67.09M
- Return on equity
- -46.00%
- Short % of float
- 13.71%
Fundamental scorecard
6 of 25 checks passed on CCCC’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 31, 2024 | Sep 1, 2024 | -0.40 | -0.35 | +0.05 | +12.50% |
| Aug 1, 2024 | Jun 1, 2024 | -0.37 | -0.26 | +0.11 | +29.73% |
| Aug 1, 2024 | Jun 1, 2024 | -0.37 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.41 | -0.41 | 0.00 | 0.00% |
| May 8, 2024 | Mar 1, 2024 | -0.41 | — | — | — |
| Feb 22, 2024 | Dec 1, 2023 | -0.67 | -0.68 | -0.01 | -1.49% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | Wells Fargo | up | Equal-Weight | Overweight |
| Nov 18, 2024 | Stephens & Co. | init | — | Equal-Weight |
| Aug 6, 2024 | BMO Capital | reit | Outperform | Outperform |
| May 9, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| May 9, 2024 | Stifel | main | Buy | Buy |
| Feb 26, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- c4therapeutics.com
News
Is C4 Therapeutics (CCCC) Outperforming Other Medical Stocks This Year? Guggenheim Maintains Buy on C4 Therapeutics, Lowers Price Target to $6
C4 Therapeutics Q3 EPS $(0.16) Beats $(0.22) Estimate, Sales $8.468M Miss $8.514M Estimate
Lake Street Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $11
Your note
Sign in to keep a note on CCCC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS KENDRA | Chief Financial Officer | Conversion of Exercise of derivative security | Nov 6, 2024 | 84,439 |
| ANDERSON KENNETH CARL | Director | Stock Award(Grant) | Sep 30, 2024 | 320,418 |
| BOYLE SCOTT N | Officer | Conversion of Exercise of derivative security | Nov 6, 2024 | 56,567 |
| DUBIN GLENN R. | Director | Stock Award(Grant) | Mar 31, 2024 | 812,682 |
| FISHER STEWART | Officer | Conversion of Exercise of derivative security | Sep 15, 2024 | 130,710 |
| GROGAN DONNA ROY M.D. | Director | Stock Award(Grant) | Sep 30, 2024 | 28,942 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Lynx1 Capital Management Lp | 9.75% | 6,880,527 | 27.93M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 9.36% | 6,603,996 | 26.81M | Sep 29, 2024 |
| Wasatch Advisors LP | 8.04% | 5,677,368 | 23.05M | Sep 29, 2024 |
| Blackrock Inc. | 6.93% | 4,890,935 | 19.86M | Sep 29, 2024 |
| RA Capital Management, L.P. | 6.91% | 4,878,000 | 19.80M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 6.20% | 4,377,900 | 17.77M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wasatch Ultra Growth Fund | 3.70% | 2,609,942 | 10.60M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 3.03% | 2,135,945 | 8.67M | Sep 29, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.34% | 1,653,493 | 6.71M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.17% | 1,534,793 | 6.23M | Oct 30, 2024 |
| Wasatch Microcap Fund | 1.76% | 1,242,144 | 5.04M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.12% | 789,707 | 3.21M | Sep 29, 2024 |
